Core Viewpoint - BioRestorative Therapies, Inc. reported strong execution in its business and key clinical milestones in 2025, with a focus on growth strategy and resource management [2] Corporate Developments - The company is in discussions with a commercial stage regenerative medicine company regarding a potential license for its ThermoStem metabolic intellectual property [4] - BioRestorative's Board of Directors authorized a stock repurchase program for up to $2 million of its common stock through June 16, 2026 [6] - Sandy Lipkins joined the company to lead strategic alliances and licensing agreements [6] Clinical Programs - The ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD) showed promising preliminary data, with over 50% improvement in both the Oswestry Disability Index (ODI) and Visual Analog Scale (VAS) [6] - The FDA requires a greater than 30% improvement in ODI and a greater than 30% reduction in VAS for trial progression and Biologics License Application (BLA) approval [6] Financial Results - For Q2 2025, the company reported revenues of approximately $303,000, a 240% increase compared to Q2 2024 [7] - The net loss for Q2 2025 was $2.7 million, or $0.30 per share, compared to a net loss of $4.0 million, or $0.50 per share, in Q2 2024 [8] - The company ended Q2 2025 with $7.4 million in cash and no outstanding debt [8]